The Effect of Thalidomide in Suppression of the Systemic Inflammatory Response Syndrome in Hemodialysis Patients

NCT ID: NCT00529633

Last Updated: 2018-04-02

Basic Information

• Recruitment Status: TERMINATED
• Clinical Phase: PHASE3
• Total Enrollment: 16 participants
• Study Classification: INTERVENTIONAL
• Study Start Date: 2007-09-30
• Study Completion Date: 2009-12-31

Brief Summary

Both malnutrition and inflammation are associated with death in dialysis patients and also with cardiovascular disease. The researchers are testing the idea that inflammation causes malnutrition by using a drug to suppress inflammation in hemodialysis patients to find out whether that will increase blood tests that are associated with malnutrition. The researchers will give hemodialysis patients who have both inflammation and malnutrition either thalidomide or a placebo and compare the effects of treatment on the levels of two proteins in the blood, albumin and prealbumin, that are normally reduced in malnourished patients. Patients who have a serum albumin concentration < 3.8 g/dl will be asked to sign consent to have blood drawn prior to dialysis for measurement of CRP (C-reactive protein). Those with CRP values ≥ 0.8 mg/dl will have a second measurement of CRP performed within 2 weeks. Those with two consecutive values of CRP ≥ 0.8 mg/dl will be eligible for enrollment

Detailed Description

4.1 Pre-assignment measurements will include:

1. Patient is eligible for enrollment.

2. Complete physical examination.

3. Blood draw at initiation of hemodialysis session

4. Instruction on birth control methods required.

5. Subjects who are non-compliant with regard to medication compliance range or birth control requirements as outlined in the S.T.E.P.S.® program will be immediately discontinued from the study

4.2 Detailed description of treatment: Patients who completed the first 4 weeks will be randomized into Treatment group. A total of 24 subjects will be studied; 12 will receive no drug and 12 will receive thalidomide. Subjects randomized to "Active" Treatment arm will receive Placebo (no-drug/sugar pill) ,or thalidomide 100 mg (two 50 mg active capsules) to take at bedtime. Weekly, Subjects will have blood drawn; will undergo a capsule count to establish a compliance range of > 85%; will have physical exam with special attention to skin and evaluation of peripheral nervous system for a change in or appearance of sensory neuropathy.

If somnolence is tolerable (subjects do not have residual somnolence in the morning) the dose will be increased to 200 mg (4 capsules).

Patients who completed 24 weeks of study will have final evaluation at week 28.

Conditions

Hypoalbuminemia

Study Design

• Allocation Method: RANDOMIZED
• Intervention Model: SINGLE_GROUP
• Primary Study Purpose: TREATMENT
• Blinding Strategy: SINGLE

Study Groups

Thalidomide

1. 12 End stage renal disease (ESRD) patients on hemodialysis for at least 3 months

2. Serum C reactive protein level of ≥ 0.8 mg/dl

3. Serum albumin < 3.8 g/dl (BCG)

4. Patients will receive 100mg Thalidomide for a period of 4 weeks; if somnolence tolerated, dosage is increased to 200mg nightly for a period of 20 more weeks -- to total of 24 weeks on Thalidomide.

Group Type: ACTIVE_COMPARATOR

Thalidomide

Intervention Type: DRUG

Thalidomide by mouth at night for a total of 24 weeks

No Drug

1. 12 End stage renal disease (ESRD) patients on hemodialysis for at least 3 months

2. Serum C reactive protein level of ≥ 0.8 mg/dl

3. Serum albumin < 3.8 g/dl (BCG)

4. Patients will receive Placebo (Sugar pill) for a period of 24 weeks.

Group Type: PLACEBO_COMPARATOR

Sugar pill

Intervention Type: OTHER

Placebo by mouth at night for a total of 24 weeks

Interventions

Thalidomide

Thalidomide by mouth at night for a total of 24 weeks

Intervention Type: DRUG

Sugar pill

Placebo by mouth at night for a total of 24 weeks

Intervention Type: OTHER

Other Intervention Names

Placebo (no drug)

Eligibility Criteria

Inclusion Criteria

1. End stage renal disease (ESRD) patients on hemodialysis for at least 3 months.

2. Serum C reactive protein level of ≥ 0.8 mg/dl.

3. Serum albumin < 3.8 g/dl (BCG).

4. Signing a written informed consent form.

5. Willingness and ability to comply with the FDA-mandated S.T.E.P.S ® program.

6. Age > 18 years.

Exclusion Criteria

1. Pregnant and/ or lactating female.

2. Active infection within the previous 8 weeks requiring administration of antibiotics.

3. Patients receiving systemic immunosuppressive therapy.

4. Patients with HIV.

• Minimum Eligible Age: 18 Years
• Eligible Sex: ALL
• Accepts Healthy Volunteers: No

Sponsors

Beth Israel Medical Center

OTHER

Sponsor Role: collaborator

George A. Kaysen, M.D.

OTHER

Sponsor Role: lead

Responsible Party

George A. Kaysen, M.D.

Professor of Medicine

Responsibility Role: SPONSOR_INVESTIGATOR

Principal Investigators

George A Kaysen, MD Ph.D

Role: PRINCIPAL_INVESTIGATOR

University of California, Davis

James F. Winchester, MD

Role: STUDY_DIRECTOR

Beth Israel Medicial Center New York New York

Locations

Beth Israel Medical Center

New York, New York, United States

Countries

United States

Other Identifiers

200614929

Identifier Type: -

Identifier Source: org_study_id